methylglyoxal; breast cancer; advanced glycation end products; Arg-pyrimidine adducts; glyoxalase
Abstract :
[en] Metabolic syndrome and type 2 diabetes are associated with increased risk of breast cancer development and progression. Methylglyoxal (MG), a glycolysis by- product, is generated through a non-enzymatic reaction from triose-phosphate intermediates. This dicarbonyl compound is highly reactive and contributes to the accumulation of advanced glycation end products. In this study, we analyzed the accumulation of Arg-pyrimidine, a MG-arginine adduct, in human breast adenocarcinoma and we observed a consistent increase of Arg-pyrimidine in cancer cells when compared with the non-tumoral counterpart. Further immunohistochemical comparative analysis of breast cancer subtypes revealed that triple negative lesions exhibited low accumulation of Arg-pyrimidine compared with other subtypes. Interestingly, the activity of glyoxalase 1 (Glo-1), an enzyme that detoxifies MG, was significantly higher in triple negative than in other subtype lesions, suggesting that these aggressive tumors are able to develop an efficient response against dicarbonyl stress. Using breast cancer cell lines, we substantiated these clinical observations by showing that, in contrast to triple positive, triple negative cells induced Glo-1 expression and activity in response to MG treatment. This is the first report that Arg- pyrimidine adduct accumulation is a consistent event in human breast cancer with a differential detection between triple negative and other breast cancer subtypes.
Chiavarina, Barbara ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases
BIANCHI, Elettra ; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique
Turtoi, Andrei ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases
Peulen, Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Peixoto, Paul ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases
Irigaray, Philippe; Association for Research and Treatments Against Cancer (ARTAC)
Uchida, Koji; Graduate School of Bioagricultural Sciences, Nagoya University > Laboratory of Food and Biodynamics
Belpomme, Dominique; Association for Research and Treatments Against Cancer (ARTAC)
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Bellahcene, Akeila ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-752.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(19):10869-10874.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ and Panel M. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22(8):1736-1747.
Penault-Llorca F and Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23 Suppl 6:vi19-22.
Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. The New England journal of medicine. 2010; 363(20):1938-1948.
Kim S, Kim do H, Jung WH and Koo JS. Metabolic phenotypes in triple-negative breast cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(3):1699-1712.
Jiang W, Zhu Z and Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer research. 2008; 68(13):5492-5499.
Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez NP and Perkins SN. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best practice & research Clinical endocrinology & metabolism. 2008; 22(4):659-669.
Sundaram S, Johnson AR and Makowski L. Obesity, metabolism and the microenvironment: Links to cancer. Journal of carcinogenesis. 2013; 12:19.
Ward PS and Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell. 2012; 21(3):297-308.
Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-1033.
Warburg O. On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-270.
Bensinger SJ and Christofk HR. New aspects of the Warburg effect in cancer cell biology. Seminars in cell & developmental biology. 2012; 23(4):352-361.
Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug metabolism and drug interactions. 2008; 23(1-2):125-150.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813-820.
Goldin A, Beckman JA, Schmidt AM and Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006; 114(6):597-605.
Yan SF, Ramasamy R, Naka Y and Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circulation research. 2003; 93(12):1159-1169.
Yan SF, Ramasamy R and Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature clinical practice Endocrinology & metabolism. 2008; 4(5):285-293.
Oudes AJ, Herr CM, Olsen Y and Fleming JE. Age-dependent accumulation of advanced glycation end-products in adult Drosophila melanogaster. Mechanisms of ageing and development. 1998; 100(3):221-229.
Morcos M, Du X, Pfisterer F, Hutter H, Sayed AA, Thornalley P, Ahmed N, Baynes J, Thorpe S, Kukudov G, Schlotterer A, Bozorgmehr F, El Baki RA, Stern D, Moehrlen F, Ibrahim Y, et al. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging cell. 2008; 7(2):260-269.
Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P and et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nature medicine. 1995; 1(7):693-699.
Kuhla B, Boeck K, Schmidt A, Ogunlade V, Arendt T, Munch G and Luth HJ. Age-and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiology of aging. 2007; 28(1):29-41.
van Heijst JW, Niessen HW, Hoekman K and Schalkwijk CG. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Annals of the New York Academy of Sciences. 2005; 1043:725-733.
Grote VA, Nieters A, Kaaks R, Tjonneland A, Roswall N, Overvad K, Nielsen MR, Clavel-Chapelon F, Boutron-Ruault MC, Racine A, Teucher B, Lukanova A, Boeing H, Drogan D, Trichopoulou A, Trichopoulos D, et al. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012; 21(4):619-628.
Xue M, Rabbani N and Thornalley PJ. Glyoxalase in ageing. Seminars in cell & developmental biology. 2011; 22(3):293-301.
Rabbani N and Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Seminars in cell & developmental biology. 2011; 22(3):309-317.
Ranganathan S and Tew KD. Analysis of glyoxalase-I from normal and tumor tissue from human colon. Biochimica et biophysica acta. 1993; 1182(3):311-316.
Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mallouh C and Konno S. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. The Journal of urology. 1999; 161(2):690-691.
Romanuik TL, Ueda T, Le N, Haile S, Yong TM, Thomson T, Vessella RL and Sadar MD. Novel biomarkers for prostate cancer including noncoding transcripts. The American journal of pathology. 2009; 175(6):2264-2276.
Bair WB, 3rd, Cabello CM, Uchida K, Bause AS and Wondrak GT. GLO1 overexpression in human malignant melanoma. Melanoma research. 2010; 20(2):85-96.
Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T and Tsuruo T. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(8):2513-2518.
Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G and Talesa V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast cancer research and treatment. 2001; 66(1):67-72.
Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M and Tsuruo T. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood. 2000; 95(10):3214-3218.
Thornalley PJ and Rabbani N. Glyoxalase in tumourigenesis and multidrug resistance. Seminars in cell & developmental biology. 2011; 22(3):318-325.
Fonseca-Sanchez MA, Rodriguez Cuevas S, Mendoza-Hernandez G, Bautista-Pina V, Arechaga Ocampo E, Hidalgo Miranda A, Quintanar Jurado V, Marchat LA, Alvarez-Sanchez E, Perez Plasencia C and Lopez-Camarillo C. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. International journal of oncology. 2012; 41(2):670-680.
Shipanova IN, Glomb MA and Nagaraj RH. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Archives of biochemistry and biophysics. 1997; 344(1):29-36.
Westwood ME and Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. Journal of protein chemistry. 1995; 14(5):359-372.
Sakamoto H, Mashima T, Yamamoto K and Tsuruo T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. The Journal of biological chemistry. 2002; 277(48):45770-45775.
Oya-Ito T, Naito Y, Takagi T, Handa O, Matsui H, Yamada M, Shima K and Yoshikawa T. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochimica et biophysica acta. 2011; 1812(7):769-781.
van Heijst JW, Niessen HW, Musters RJ, van Hinsbergh VW, Hoekman K and Schalkwijk CG. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer letters. 2006; 241(2):309-319.
Sosa V, Moline T, Somoza R, Paciucci R, Kondoh H and ME LL. Oxidative stress and cancer: an overview. Ageing research reviews. 2013; 12(1):376-390.
Visconti R and Grieco D. New insights on oxidative stress in cancer. Current opinion in drug discovery & development. 2009; 12(2):240-245.
Pani G, Galeotti T and Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer metastasis reviews. 2010; 29(2):351-378.
Rabbani N and Thornalley PJ. Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino acids. 2012; 42(4):1133-1142.
Giacco F, Du X, D'Agati VD, Milne R, Sui G, Geoffrion M and Brownlee M. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes. 2014; 63(1):291-299.
Thornalley PJ, Hooper NI, Jennings PE, Florkowski CM, Jones AF, Lunec J and Barnett AH. The human red blood cell glyoxalase system in diabetes mellitus. Diabetes research and clinical practice. 1989; 7(2):115-120.
Szent-Gyorgyi A. Bioelectronics. Intermolecular electron transfer may play a major role in biological regulation, defense, and cancer. Science. 1968; 161(3845):988-990.
Antognelli C, Mezzasoma L, Fettucciari K and Talesa VN. A novel mechanism of methylglyoxal cytotoxicity in prostate cancer cells. The international journal of biochemistry & cell biology. 2013; 45(4):836-844.
Kang Y, Edwards LG and Thornalley PJ. Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leukemia research. 1996; 20(5):397-405.
Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. General pharmacology. 1996; 27(4):565-573.
Nakadate Y, Uchida K, Shikata K, Yoshimura S, Azuma M, Hirata T, Konishi H, Kiyama H and Tachibana T. The formation of argpyrimidine, a methylglyoxal-arginine adduct, in the nucleus of neural cells. Biochemical and biophysical research communications. 2009; 378(2):209-212.
Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK and Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Molecular & cellular proteomics: MCP. 2005; 4(11):1686-1696.
Amicarelli F, Bucciarelli T, Poma A, Aimola P, Di Ilio C, Ragnelli AM and Miranda M. Adaptive response of human melanoma cells to methylglyoxal injury. Carcinogenesis. 1998; 19(3):519-523.
Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ and Double J. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochemical pharmacology. 1996; 51(10):1365-1372.
Kalapos MP. The tandem of free radicals and methylglyoxal. Chemico-biological interactions. 2008; 171(3):251-271.
Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T and Uchida K. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. The Journal of biological chemistry. 1999; 274(26):18492-18502.
Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J and Castronovo V. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. Journal of the National Cancer Institute. 1998; 90(13):1000-1008.